These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 158847)

  • 1. Fibrinolysis of soluble and polymerized des-AA/des-AABB fibrin compared to fibrinogenolysis in buffer and in fibrinogen-boosted serum. Evidence that plasminogen activators are responsible for preferential degradation of polymerized fibrin.
    Brosstad F
    Thromb Res; 1979; 15(3-4):497-504. PubMed ID: 158847
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: Fibrinolysis versus fibrinogenolysis: the specificity of human vascular activator (VA) as compared to urokinase (UK) and streptokinase (SK).
    Lipinski B; Gurewich V; Hyde E
    Thromb Diath Haemorrh; 1975 Sep; 34(1):351. PubMed ID: 1188799
    [No Abstract]   [Full Text] [Related]  

  • 3. The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs.
    Gurewich V; Hyde E; Lipinski B
    Blood; 1975 Oct; 46(4):555-65. PubMed ID: 126095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolution of thrombi by tissue plasminogen activator, urokinase and streptokinase in an artificial circulating system.
    Mattsson C; Nyberg-Arrhenius V; Wallén P
    Thromb Res; 1981 Mar; 21(6):535-45. PubMed ID: 7022741
    [No Abstract]   [Full Text] [Related]  

  • 5. [Molecular mechanisms of thrombolytic therapy].
    Lijnen HR; Collen D
    Haemostasis; 1986; 16 Suppl 4():3-15. PubMed ID: 2945768
    [No Abstract]   [Full Text] [Related]  

  • 6. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain.
    Summaria L; Boreisha IG; Arzadon L; Robbins KC
    Thromb Res; 1977 Sep; 11(3):377-89. PubMed ID: 144332
    [No Abstract]   [Full Text] [Related]  

  • 7. Alpha 2-plasmin inhibitor deficiency.
    Lipinski B; Gurewich V
    Lancet; 1979 Feb; 1(8111):329. PubMed ID: 84984
    [No Abstract]   [Full Text] [Related]  

  • 8. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
    Cassels R; Fears R; Smith RA
    Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The search for the ideal thrombolytic agent.
    Verstraete M
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.
    Pannell R; Li S; Gurewich V
    J Thromb Thrombolysis; 2017 Aug; 44(2):210-215. PubMed ID: 28600623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin.
    Camiolo SM; Thorsen S; Astrup T
    Proc Soc Exp Biol Med; 1971 Oct; 138(1):277-80. PubMed ID: 5125527
    [No Abstract]   [Full Text] [Related]  

  • 13. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolysis--a review.
    Kane KK
    Ann Clin Lab Sci; 1984; 14(6):443-9. PubMed ID: 6239587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New thrombolytic agents].
    Nguyen G; Samama M
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QUANTITATIVE ESTIMATION OF UROKINASE AND BACTERIAL PLASMINOGEN ACTIVATORS USING A FIBRIN SUBSTRATE FORMED FROM PLASMINOGEN-FREE FIBRINOGEN.
    ANDERSON AJ
    Biochim Biophys Acta; 1963 Aug; 74():554-7. PubMed ID: 14071603
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products.
    Khavkina LS; Rozenfeld MA; Leonova VB
    Thromb Res; 1995 Apr; 78(2):173-87. PubMed ID: 7482434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glu-plasminogen I and II: their activation by urokinase and streptokinase in the presence of fibrin and fibrinogen.
    Takada Y; Makino Y; Takada A
    Thromb Res; 1985 Aug; 39(3):289-96. PubMed ID: 4049320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
    Trübestein G; Popov S; Wolf H; Welzel D
    Haemostasis; 1987; 17(4):238-44. PubMed ID: 2442078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.